안구건조증 시장 규모, 점유율, 성장 분석 : 제품별, 제형별, 유통경로별, 지역별 - 업계 예측(2025-2032년)

Global Dry Eye Syndrome Market size was valued at USD 7.7 billion in 2023 and is poised to grow from USD 8.31 billion in 2024 to USD 15.26 billion by 2032, growing at a CAGR of 7.9% during the forecast period (2025-2032).

Market insights for the global dry eye syndrome (DES) segment indicate a notable shift towards prescription therapies targeting inflammatory mechanisms, moving away from over-the-counter lubricants. Innovative prescription drug technologies are emerging, focusing on disease-modifying treatments that address concerns like meibomian gland dysfunction, ocular surface inflammation, and tear-film instability. This growth is further fueled by the increasing prevalence of dry eye disease, particularly among the aging population and those with related health conditions. The demographic of individuals over 60 is expanding rapidly, contributing to the rising incidence globally. Currently, millions are affected by significant dry eye, with cases rising in regions such as Europe and East Asia, highlighting the necessity for effective, targeted treatment options in this evolving market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dry Eye Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Dry Eye Syndrome Market Segments Analysis

Global Dry Eye Syndrome Market is segmented by Product, Dosage Form, Distribution Channel and region. Based on Product, the market is segmented into Over the Counter (OTC) Artificial Tears & Lubricants, Prescription Drugs, Punctual Plugs, Nutraceuticals & Omega-3 Supplements and Autologous Serum & Blood-Derived Tear Substitutes. Based on Dosage Form, the market is segmented into Eye Drops and Ointments & Gels. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Independent Pharmacies & Drug Stores and Online Pharmacies & E-Commerce Portals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Dry Eye Syndrome Market

The Global Dry Eye Syndrome market is significantly influenced by the growing aging population alongside an increase in the prevalence of dry eye conditions. As more elderly individuals require ongoing eye care, there is a corresponding demand for both prescription and over-the-counter treatments. Additionally, the surge in screen time among individuals contributes to an immediate uptick in lubricant sales and may create a sustained need for therapeutic interventions. North America currently stands out as a leading market, indicating a robust potential for revenue growth. Consequently, the landscape is ripe for innovative treatments and diagnostic services, ensuring ongoing opportunities in this sector.

Restraints in the Global Dry Eye Syndrome Market

Despite the widespread occurrence of dry eye disease (DED), a significant number of patients remain undiagnosed and untreated. Often, individuals choose not to consult a healthcare professional, opting instead for self-treatment using over-the-counter eye drops. This behavior limits the revenue potential for medications specifically developed to manage or progress the condition effectively, while also complicating the transition to prescription treatments. The relatively low percentage of diagnosed patients who receive prescription medication impedes the overall growth potential of utilizing more advanced and costly therapeutic options. Consequently, these factors represent considerable constraints within the global dry eye syndrome market.

Market Trends of the Global Dry Eye Syndrome Market

The Global Dry Eye Syndrome market is experiencing a significant trend towards prescription medications and treatments that target the underlying disease process rather than merely alleviating symptoms. Clinicians are increasingly shifting their preference towards innovative therapies that focus on enhancing tear film stability and addressing inflammatory pathways. This evolution is supported by the emergence of new pharmacological options, including peptides, neurostimulatives, and sustained-release formulations, alongside the initiation of groundbreaking clinical trials. Furthermore, the rise of specialty clinics and tailored formularies is redefining treatment paradigms, positioning the market for substantial growth as the focus transitions to long-term management strategies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Dry Eye Syndrome Market Size by Product & CAGR (2025-2032)

• Market Overview
• Over the Counter (OTC) Artificial Tears & Lubricants
• Prescription Drugs
• Punctual Plugs
• Nutraceuticals & Omega-3 Supplements
• Autologous Serum & Blood-Derived Tear Substitutes

Global Dry Eye Syndrome Market Size by Dosage Form & CAGR (2025-2032)

• Market Overview
• Eye Drops
• Ointments & Gels

Global Dry Eye Syndrome Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacies
• Independent Pharmacies & Drug Stores
• Online Pharmacies & E-Commerce Portals

Global Dry Eye Syndrome Market Size & CAGR (2025-2032)

• North America (Product, Dosage Form, Distribution Channel)
  • US
  • Canada
• Europe (Product, Dosage Form, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Dosage Form, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Dosage Form, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Dosage Form, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch + Lomb (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kala Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novaliq GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AFT Pharmaceuticals (New Zealand)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aldeyra Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OASIS Medical (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akorn Operating Company LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nicox S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocular Therapeutix, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitotech S.A. (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tarsus Pharmaceuticals, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Stuart Therapeutics (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations